ADVFN Logo ADVFN
Donnée du Marché
Actualité
Outils
Donnée du Marché
Discover

Hot Features

Follow Feed

Rester connecter avec les traders et investisseurs dans notre communauté Follow Feed.

Flux des Options

Explorez des données complètes sur les options et utilisez les filtres avancés avec Options Flow.

Moniteur

Organisez et surveillez vos d'actions et actifs avec le Moniteur.
Se connecter Premium IconPremium Help Menu
CAC 40
8 094,97
-0,09%
Dow Jones
39 069,59
0,01%
DAX
18 693,37
0,04%
Brent Oil
81,965
0,00%
Bitcoin
69 089,50
0,82%
Registration Strip Icon for monitor Surveillez plusieurs cotations en temps réel des principales bourses, telles que Euronext Paris, NASDAQ, NYSE, AMEX, Bovespa et plus encore.
S'inscrire
  1. Accueil
  2. Investir
  3. Actions
  4. Etats-Unis
  5. NASDAQ
  6. Grifols SA (GRFS)

  7. Grifols SA (GRFS) Actualités

GRFS

Grifols (GRFS)

Grifols SA
De:
Trier par:
 Showing the most relevant articles for your search:NASDAQ:GRFS
DateHeureSourceTitreSymboleSociété
19/04/202422h42PR Newswire (US)Grifols 2023 Annual Report on Form 20-F filed with the SECNASDAQ:GRFSGrifols SA
18/04/202415h30GlobeNewswire Inc.Grifols Celebrates 50 Years of Manufacturing Life-Changing Plasma-Derived Medicines for Patients at Flagship Site in Clayton, N.C.NASDAQ:GRFSGrifols SA
15/04/202413h06IH Market NewsSamsung Surpasses Apple in Q1 Smartphone Market; Salesforce in Talks to Acquire Informatica, and More NewsNASDAQ:GRFSGrifols SA
04/04/202410h00GlobeNewswire Inc.Grifols Procleix ArboPlex Assay® Receives CE Mark, the First and Only 4-in-1 NAT for Arbovirus ScreeningNASDAQ:GRFSGrifols SA
22/03/202414h07IH Market NewsFedEx Soars 13% with Profits Above Forecasts, Nike Hit by China Slowdown, and Latest NewsNASDAQ:GRFSGrifols SA
08/03/202412h19IH Market NewsCNOOC Oil Field Discovery in South China Sea, Grifols Surges 18% After KPMG Approval, and Latest NewsNASDAQ:GRFSGrifols SA
14/02/202409h16GlobeNewswire Inc.Grifols announces positive topline phase 3 fibrinogen clinical trial resultsNASDAQ:GRFSGrifols SA
26/01/202423h14Edgar (US Regulatory)Form 6-K - Report of foreign issuer [Rules 13a-16 and 15d-16]NASDAQ:GRFSGrifols SA
12/01/202412h10IH Market NewsWall Street Highlights: DocuSign Acquisition Battle, Tesla Berlin Production Halt, and MoreNASDAQ:GRFSGrifols SA
10/01/202412h21IH Market NewsWall Street Highlights: Tesla Launches Restyled Model 3, VinFast Unveils Pickup Prototype, and MoreNASDAQ:GRFSGrifols SA
29/12/202315h59Dow Jones NewsGrifols Shares Rise on $1.76 Billion Sale of 20% Stake in Shanghai RAAS to Pay Down DebtNASDAQ:GRFSGrifols SA
16/11/202311h00PR Newswire (US)Grifols launches new solution to facilitate pre-transfusion compatibility testing in multiple myeloma patientsNASDAQ:GRFSGrifols SA
15/11/202314h00GlobeNewswire Inc.Grifols Completes Cohort 1 in Clinical Study of Alpha-1 15%, Evaluating First-in-Human Subcutaneous Dosing Option for Patients with Alpha1-Antitrypsin DeficiencyNASDAQ:GRFSGrifols SA
06/11/202314h00GlobeNewswire Inc.GigaGen Presents IND-Enabling Data and Phase 1 Trial Strategy for its Novel Anti-CTLA-4 Oncology Drug Candidate, GIGA-564, at SITC 2023NASDAQ:GRFSGrifols SA
25/10/202300h30GlobeNewswire Inc.Araclon Biotech Presents Positive Final Results from Phase 2 Clinical Study of ABvac40 Alzheimer’s Vaccine at CTADNASDAQ:GRFSGrifols SA
19/10/202314h00GlobeNewswire Inc.GigaGen Granted Expansion of Contract with US Department of Defense to Develop Synthetic Human Antibody Treatments for Botulinum NeurotoxinsNASDAQ:GRFSGrifols SA
28/09/202314h00GlobeNewswire Inc.GigaGen Partners with the National Cancer Institute to Advance Oncology Drug Candidate GIGA-564NASDAQ:GRFSGrifols SA
01/08/202314h00GlobeNewswire Inc.Grifols Accelerates Healthcare Innovation with Google Cloud’s AI and AnalyticsNASDAQ:GRFSGrifols SA
20/07/202314h15GlobeNewswire Inc.Grifols Achieves Positive Topline Results From Phase 4 Study of XEMBIFY® (immune globulin subcutaneous human-klhw) Evaluating Biweekly Dosing Option for PatientsNASDAQ:GRFSGrifols SA
18/07/202314h00GlobeNewswire Inc.Grifols Completes Enrollment in Phase 3 Study of Long-term Albutein® (albumin-human injection) Therapy for Patients with Decompensated CirrhosisNASDAQ:GRFSGrifols SA
13/07/202314h00GlobeNewswire Inc.Grifols Meets Enrollment Target in Phase 3 Study of Two Dose Regimens of Prolastin®-C in Patients with Emphysema Due to Alpha-1-Antitrypsin DeficiencyNASDAQ:GRFSGrifols SA
20/06/202313h13Edgar (US Regulatory)Report of Foreign Issuer Pursuant to Rule 13a-16 or 15d-16 (6-k)NASDAQ:GRFSGrifols SA
15/06/202301h34Dow Jones NewsADRs End Higher, Grifols, Victrex Trade ActivelyNASDAQ:GRFSGrifols SA
14/06/202312h44Dow Jones NewsGrifols Shares Rise on Potential Sale of Shanghai RAAS Stock for $1.5 BillionNASDAQ:GRFSGrifols SA
11/05/202314h30GlobeNewswire Inc.Grifols Launches AlphaID™ At Home, Enabling U.S. Consumers to Self-Screen for Genetic COPDNASDAQ:GRFSGrifols SA
10/05/202301h31Dow Jones NewsADRs End Mostly Lower, Natura & Co. and Grifols Trade ActivelyNASDAQ:GRFSGrifols SA
18/04/202316h30PR Newswire (US)Grifols 2022 Annual Report on Form 20-F filed with the SEC on April 18, 2023NASDAQ:GRFSGrifols SA
18/04/202315h27Edgar (US Regulatory)Annual and Transition Report (foreign Private Issuer) (20-f)NASDAQ:GRFSGrifols SA
06/03/202313h00PR Newswire (US)Selagine Enters into a Collaborative Agreement with Grifols for Development and Commercialization of Immunoglobulin Eye Drops for Treating Dry Eye DiseaseNASDAQ:GRFSGrifols SA
05/12/202213h05TipRanksGrifols SA (GRFS) Gets a Hold from J.P. MorganNASDAQ:GRFSGrifols SA
 Showing the most relevant articles for your search:NASDAQ:GRFS

Dernières Valeurs Consultées

NYSE
AM
Antero Midstream
Delayed Upgrade Clock
ADVFN Logo
InvestorsHub

France
Société
Entreprise
Popular
Obtenir l'application
App Store
Google Play

Assistance: support@advfn.fr

En accédant aux services disponibles de ADVFN, vous acceptez les Conditions Générales de ADVFN Conditions Générales

© 2024 ADVFN PLC - Tous droits réservés